TMS
TMS is a Tokyo-based clinical-stage biotech company that unlocks fungus-derived SMTP small molecule compound group. SMTPs have novel dual mode of action, both thrombolytic and anti-inflammatory. The lead compound TMS-007 is in Phase IIa clinical trial indicated for acute ischemic stroke and partnered with Biogen.
TMS
Industry:
Biotechnology Life Science Medical Nursing And Residential Care Pharmaceutical
Founded:
2005-02-17
Address:
Fuchu, Tokyo, Japan
Country:
Japan
Website Url:
http://www.tms-japan.co.jp
Total Employee:
11+
Status:
Active
Contact:
+81-42-306-5087
Email Addresses:
[email protected]
Total Funding:
910.25 M JPY
Technology used in webpage:
SPF Font Awesome Apache
Similar Organizations
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Current Employees Featured
Founder
Investors List
77 Capital
77 Capital investment in Venture Round - TMS
Nissay Capital
Nissay Capital investment in Series C - TMS
Oita Venture Capital
Oita Venture Capital investment in Series C - TMS
Mitsubishi UFJ Capital
Mitsubishi UFJ Capital investment in Series C - TMS
Tohoku University Venture Partners
Tohoku University Venture Partners investment in Series C - TMS
Sansei Capital Investment
Sansei Capital Investment investment in Series C - TMS
MITSUI SUMITOMO INSURANCE Venture Capital (MSIVC)
MITSUI SUMITOMO INSURANCE Venture Capital (MSIVC) investment in Series C - TMS
KSP
KSP investment in Convertible Note - TMS
Mitsubishi UFJ Capital
Mitsubishi UFJ Capital investment in Convertible Note - TMS
Japan Asia Investment
Japan Asia Investment investment in Convertible Note - TMS
More informations about "TMS"
HOME | TMS Co., Ltd. - tms-japan.co.jp
Dec 18, 2024 TMS to participate in Precision AQ Corporate Access Event During J.P.Morgan 2025 Week in San Francisco （201KB） Nov 15, 2024 TMS Co., Ltd. CEO Takuro Wakabayashi Interviewed on US Internet News Media 'Biotech …See details»
About Us | TMS Co., Ltd. - tms-japan.co.jp
You can see the About Us of TMS Co., Ltd..See details»
Company Info | About Us | TMS Co., Ltd. - tms-japan.co.jp
Address. Headquaters: 1-9-11F, Fuchu-cho, Fuchu-shi, Tokyo 183-0055, JAPANSee details»
Developing revolutionary drugs for diseases without effective …
Initial research efforts were concentrated on TMS-007, an SMTP compound. TMS-007, which dissolves blood clots and controls inflammation, is anticipated to be highly effective for treating …See details»
TMS - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number +81-42-306-5087 TMS is a Tokyo-based clinical-stage biotech company that unlocks fungus-derived SMTP small molecule compound group.See details»
Management Team | About Us | TMS Co., Ltd. - tms-japan.co.jp
During his tenure at TMS, he led deals with Biogen and Ji-Xing (now CORXEL) and led the company’s initial public offering in 2022, which is the first global IPO by a Japan-based biotech …See details»
TMS Japan - Crunchbase Company Profile & Funding
Organization. TMS Japan . Connect to CRM . Save . Summary. Financials. People. Signals & News. Similar Companies. ... Legal Name TMU Science Co., Ltd. Company Type For Profit; …See details»
TMS Co., Ltd. - LinkedIn
Aug 5, 2023 TMS Co., Ltd. | 17 followers on LinkedIn. ... ネクセラファーマ株式会社 Biotechnology Research 千代田区, 東京都See details»
History | About Us | TMS Co., Ltd. - tms-japan.co.jp
In June 2018, TMS signed an option agreement to assign TMS-007, its lead program indicating acute ischemic stroke, and related assets to Biogen for a total of $ 357 million milestone …See details»
TMS Co., Ltd. Highlights 2024 Achievements and 2025 Goals in ...
4 days ago More about TMS Co., Ltd. TMS Co., Ltd. is a clinical-stage biopharmaceutical company that focuses on discovering and developing transformative medicines to address …See details»
TMS CO., LTD. Company Profile | FUCHU, TOKYO, Japan
Find company research, competitor information, contact details & financial data for TMS CO., LTD. of FUCHU, TOKYO. Get the latest business insights from Dun & Bradstreet.See details»
Board of Directors | About Us | TMS Co., Ltd. - tms-japan.co.jp
Takanashi brings into TMS deep global business experience in biomedical field. Mr. Takanashi currently serves as Executive Vice President, Head of Global Business at Shin Nippon …See details»
根拠に基づく腰痛治療―TMSジャパン公式サイト
なお、TMSジャパンは篤志家のサポートで成り立つ非営利組織であり、運営は腰痛治療セミナー・個人治療プログラム・腰痛の原因と治療に関する講演会・腰痛治療セミナーのDVD販売 …See details»
Corporate Presentation - tms-japan.co.jp
Transferred ex-Japan rights from Biogen to CORXEL January 2024 JX09 (Resistant or uncontrolled hypertension) First subject dosed in Ph1 study in Australia February 2024 In …See details»
NEWS RELEASE - tms-japan.co.jp
About TMS Co., Ltd. TMS Co., Ltd. is a clinical- stage biopharmaceutical company focused on the discovery and development of transformative medicines for the treatment of serious diseases …See details»
Corporate Presentation | IR Library | Investor Relations | TMS Co., Ltd.
You can see the Corporate Presentation of TMS Co., Ltd..See details»
NEWS RELEASE - tms-japan.co.jp
Corxelが主導するtms-007の国際共同治験の開始。当社は日本のパートナーとしてこの治験に参加する 予定です。 2025年5月末までに、tms-008の第1相臨床試験の結果を報告し、安全性、 …See details»
NEWS RELEASE - tms-japan.co.jp
開発中のJX10/TMS-007 及びTMS-008 の標的タンパクの一つである可溶性エポキシドヒドロラーゼ ... E-mail：[email protected] 分子機能研究所 広報担当 TEL/FAX：048－956－6985 E …See details»
Pipeline | Business | TMS Co., Ltd. - tms-japan.co.jp
Cookie Policy. We use cookies to provide you with a better browsing experience. Please confirm that you agree to our use of cookies by clicking Yes.See details»
NEWS RELEASE - tms-japan.co.jp
リードパイプラインであるtms-007（jx10）は、急性期脳梗塞治療薬として前期第Ⅱ相臨床試験において有効 性と安全性を示しました。その他に、治療抵抗性又は制御不能な高血圧、急性 …See details»